Abstract Purpose: To evaluate the performance of the Ranger paclitaxel-coated balloon vs uncoated balloon angioplasty for femoropopliteal lesions. Methods: Between January 2014 and October 2015, the prospective, randomized RANGER SFA study (ClinicalTrials.gov identifier NCT02013193) enrolled 105 patients with symptomatic lower limb ischemia (Rutherford category 2-4) and stenotic lesions in the nonstented femoropopliteal segment at 10 European centers. Seventy-one patients (mean age 68±8 years; 53 men) were enrolled in the Ranger drug-coated balloon (DCB) arm and 34 patients (mean age 67±9 years; 23 men) were assigned to the control group. Six-month analysis included angiographic late lumen loss and safety and clinical outcomes assessments. Results: Baseline characteristics of the DCB and control groups were similar, as were lesion lengths (68±46 vs 60±48 mm; p=0.731), severity of calcification (p=0.236), and the prevalence of occlusions (34% vs 34%; p>0.999). At 6 months, late lumen loss was significantly less for the DCB group vs controls (-0.16±0.99 vs 0.76±1.4; p=0.002). The DCB group had significantly greater freedom from binary restenosis (92% vs 64%; p=0.005) and primary patency rates (87% vs 60%; p=0.014). Target lesion revascularization rates were 5.6% in the DCB group and 12% in the control group (p=0.475). No target limb amputations or device-related deaths occurred in either group. Conclusion: Six-month results suggest that Ranger DCB treatment effectively inhibited restenosis in symptomatic femoropopliteal disease, resulting in improved vessel patency and a low revascularization rate in the short term compared with uncoated balloon angioplasty.
Introduction
Atherosclerotic peripheral artery disease (PAD) affects a growing number of patients in aging Western populations. 1 PAD is highly associated with cardiovascular mortality and morbidity, and smoking cessation, lifestyle modification, and medical treatment, along with concomitant evaluation for cardiovascular risk, is a well-established treatment regimen. 2 However, the symptoms of PAD often lead to decreased quality of life and reduced functional independence, so endovascular revascularization or surgical reconstruction often becomes necessary to restore blood flow to the diseased limb. While balloon angioplasty and stent implantation in stenosed or occluded vessel segments have achieved satisfactory initial results, 3 restenosis remains a challenge, particularly in the treatment of femoropopliteal lesions. Antiproliferative agents, such as paclitaxel, delivered into the vessel wall by drug-coated balloons (DCB) 4 or drug-eluting stents 5, 6 have been shown to inhibit restenosis and improve patency in the infrainguinal arteries compared with uncoated balloon angioplasty alone. DCB and drugeluting stent strategies are both currently being investigated to optimize interventional treatment of infrainguinal atherosclerotic vascular obstructions.
Extent of disease, its anatomic location, and metabolic factors (eg, calcification, presence of diabetes) influence outcomes of interventional treatment and may affect the success of different drug technologies. In published randomized trials of femoropopliteal disease, [7] [8] [9] [10] DCBs were generally studied in focal or short lesions, while long, complex disease or severe calcification were excluded to prevent primary angioplasty failure and to minimize bailout stenting.
Preclinical studies 11, 12 and initial DCB trials 8, 13 have highlighted the importance of paclitaxel and excipient formulation for rapid drug delivery into the vessel wall during balloon inflation. The TransPax coating of the Ranger Paclitaxel-Coated Balloon Catheter (Boston Scientific, Marlborough, MA, USA; Hemoteq AG, Würselen, Germany) includes a novel citric ester excipient intended to optimize paclitaxel microcrystallinity to increase drug transfer to the arterial wall and sustain therapeutic drug tissue levels. A preclinical swine study demonstrated that the Ranger paclitaxel dose was associated with significant neointimal inhibition and good vascular healing.
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The purpose of the RANGER SFA randomized clinical study was to evaluate the performance of the Ranger paclitaxel-coated balloon catheter vs an uncoated balloon for angioplasty of femoropopliteal lesions, specifically investigating the hypothesis that 6-month late lumen loss is less following treatment with the Ranger balloon than with an uncoated balloon.
Methods

Study Design
The prospective, multicenter, randomized, controlled study of the Ranger DCB for treatment of the superficial femoral artery (SFA) and proximal popliteal segment in patients with symptoms of PAD was designed to compare the 6-month angiographic late lumen loss associated with Ranger DCB vs conventional balloon treatment. Patients were randomly assigned in a 2:1 ratio to treatment with the Ranger DCB or an uncoated balloon. Enrollment and randomization occurred after a guidewire had crossed the target lesion and prior to balloon angioplasty. Randomly permuted blocks with random block sizes were used to generate the randomization sequence. Every study center received a set of opaque envelopes comprising the randomized assignments before patients were recruited. At the time of a patient's enrollment, the next envelope in the sequence was opened to reveal the individual treatment assignment. Patients and operators were not blinded to the assigned treatment, but a blinded independent core laboratory (CoreLab Bad Krozingen GmbH, Bad Krozingen, Germany) analyzed the quantitative vascular angiography and duplex ultrasonography data collected in the study.
The study protocol was approved by the ethics committees at each trial site, and all patients provided written informed consent prior to enrollment. The study was conducted in accordance with good clinical practice standards, ethical principles that have their origins in the Declaration of Helsinki, and pertinent individual country laws and regulations. For German sites, additional approval from the German radiation board (Bundesamt für Strahlenschutz) was required for subjects to undergo angiography for the primary endpoint. The trial was registered on the National Institutes of Health website (ClinicalTrials.gov; identifier NCT02013193).
Inclusion/Exclusion Criteria
Patients eligible for the study were adults with symptoms of lower limb ischemia, defined as Rutherford category 2-4, and a hemodynamically significant (≥70% stenosis by visual assessment) de novo or restenotic lesion between 20 and 150 mm in length located in the native nonstented SFA or proximal popliteal segment. Patients were required to have at least 1 infrapopliteal artery with good runoff (<50% stenosis) to the foot prior to the index procedure. Successful intraluminal wire crossing of the target lesion without the use of adjunctive therapies such as atherectomy or thrombectomy was required before randomization and enrollment. Only one lesion per limb could be treated.
Among the exclusion criteria were prior surgery of the target femoropopliteal segment to treat atherosclerotic disease; major amputation in the target limb; aneurysm in the target vessel; acute ischemia and/or acute thrombosis in either lower limb; persisting intraluminal thrombus in the proposed target lesion post thrombolytic therapy; known hypersensitivity or contraindication to contrast dye, paclitaxel, or other components of the used medical devices; and intolerance to antiplatelet, anticoagulant, or thrombolytic medications administered during the trial. A full list of inclusion/exclusion criteria is available at https://www.clinicaltrials.gov/ct2/show/NCT02013193.
Study Device and Treatment
The Ranger DCB TransPax coating includes paclitaxel at a dose density of 2 μg/mm 2 and acetyl tri-n-butyl citrate excipient. The Ranger device includes a loading tool designed to protect the balloon coating during transfer, thereby reducing systemic drug loss. Aside from the device coating and loading tool, the components of the Ranger DCB are identical to the commercially available Sterling (0.018-inch wire-compatible) balloon dilation catheter (Boston Scientific).
DCB diameters of 4 to 7 mm and lengths from 40 to 100 mm were available for use in the study. Predilation with a noncoated, smaller diameter balloon was mandated in the study protocol. The Ranger DCB was to be inflated only once, and balloon sizing was therefore intended to treat the lesion with a single balloon that fully covered the targeted vessel segment. If additional balloons were required, overlap was to be minimized (ie, limited to no more than 0.5-1 cm). Patients assigned to the control arm could be treated with any non-drug-coated balloon available in an appropriate size. The study protocol allowed stenting (bare metal stents only) at the physician's discretion in situations such as flow-limiting dissections that could not be repaired with prolonged balloon inflation alone.
Patients in both study arms were to follow a dual antiplatelet therapy (DAPT) regimen that included minimum loading doses of 300 mg acetylsalicylic acid and 300 mg clopidogrel. A DAPT regimen (minimum 75 mg/d acetylsalicylic acid and minimum 75 mg/d of a P2Y12 inhibitor such as clopidogrel) was to continue for at least 4 weeks following the index procedure, and at least one antiplatelet drug was to be continued indefinitely thereafter. Alternative DAPT regimens could be followed if justified by individual patient requirements.
Follow-up
Follow-up was conducted by telephone at 1 month after the procedure to assess adverse events; a 6-month (±30 days) in-office assessment included angiography, duplex ultrasonography, and assessments of clinical outcomes [ankle-brachial index (ABI) and Rutherford category), walking function, and quality of life. All assessments except angiography will be repeated at 1 year. Overall study follow-up, including adverse event reporting, quality of life assessments, and annual clinic visits, will continue for 3 years.
Patient Population
Between January 2014 and October 2015, a total of 105 patients were enrolled at 10 European centers (Supplemental Table S1 ; supplementary material available at http://jet. sagepub.com/content/by/supplemental-data). Seventy-one patients (mean age 68±8 years; 53 men) were randomized to the Ranger DCB arm and 34 patients (mean age 67±9 years; 23 men) were assigned to the control group. Patient flow is depicted in Figure 1 . Clinical and lesion characteristics are shown in Tables 1 and 2 , respectively. Angiographic calcium was graded according to the criteria developed by Dattilo et al. 14 According to the core laboratory, more than half of the lesions had moderate (ie, calcium deposits <180° in circumference and ≥50% of lesion length) to severe (deposits ≥180° in circumference and ≥50% of lesion length) calcification. The proportion of occlusions (34%) was equal in both groups (Table 2 ). Lesion lengths (68±46 vs 60±48 mm) were similar between the DCB and control groups.
Study Endpoints and Definitions
The primary endpoint was angiographic in-segment late lumen loss defined as the difference in minimum lumen diameter measurements at postprocedure to 6 months (±30 days) as evaluated by the core laboratory using postprocessing software (QAngioXA; Medis medical imaging systems, Leiden, the Netherlands).
Secondary outcomes included acute technical success, procedure success, patency (binary restenosis and primary patency), clinical outcomes, walking function, and quality of life at 6 months. Technical success was defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis ≤30% (site assessment). Procedure success was defined as technical success with no major adverse events [ie, device/procedure-related death, target limb major amputation, or target lesion revascularization (TLR)] within 24 hours of the study procedure. Clinical success was defined as improvement in Rutherford category by at least 1 level compared with baseline. Hemodynamic success was defined as a positive change in ABI of at least 0.1.
Binary restenosis and primary patency rates were based on duplex ultrasound evaluations at 6 months. The blinded core laboratory (CoreLab Bad Krozingen GmbH) used a peak systolic velocity ratio threshold >2.4 to define restenosis. Primary patency was defined as freedom from duplexidentified restenosis, TLR, or bypass of the target lesion.
The changes in Rutherford category and ABI from baseline to 6 months were used to assess clinical outcomes. The Walking Impairment Questionnaire (WIQ) was administered at baseline and 6 months in order to evaluate differences in walking function between the Ranger and control groups. General health-related quality of life was assessed with the EQ-5D-3L (EuroQol health status measurement tool in 5 dimensions; EuroQol, Rotterdam, the Netherlands) 15, 16 and SF-12v2 17, 18 (Optum, Eden Prairie, MN, USA) questionnaires. SF-12v2 scores range from 0 to 100 with greater values indicating better quality of life; scoring was completed with Health Outcomes Scoring software (version 4.5; Optum).
Statistical Analysis
The hypothesis for the primary study endpoint was that the 6-month angiographic late lumen loss for patients treated with the Ranger DCB would be significantly less than for patients treated with a non-drug-coated balloon. Enrollment was targeted at 105 patients to have an analyzable minimum sample size of 78 subjects (52 in the Ranger DCB group and 26 in the control group) for angiographic late lumen loss at 6 months assuming at least 25% attrition, which was expected to be higher for the 6-month angiogram than for the visit itself due to the invasive nature of angiography. The desired sample size was calculated to provide at least 80% power using a 1-sided t test with a significance level of 0.05, assuming a true difference of 0.6 mm in late lumen loss between the groups.
Continuous data are presented as the means ± standard deviation; categorical data are given as the counts (percentage). Late lumen loss was compared between groups with a 1-sided t test for normal distributions (confirmed using the Lilliefors test). Two post hoc comparisons of lumen loss were conducted to evaluate the potential influence of stenting: one between the control and Ranger DCB groups including only patients who did not have bailout stenting (1-sided t test) and another between patients with and without stenting within the Ranger DCB group (2-sided t test).
Baseline and secondary endpoint comparisons between the Ranger DCB and control groups were conducted with the following statistical tests, depending on the nature of the variables compared: 2-sample 2-sided KolmogorovSmirnov test (interval scaled variables), Kruskal-Wallis rank sum test (ordinal scaled variables), and chi-square independence test (nominal scaled variables). The significance level for all tests was 0.05. For ABI, values greater than the clinically feasible threshold of 1.5 were excluded from analysis. Data were analyzed using R (version 3.2.4; R Foundation for Statistical Computing, Vienna, Austria).
Results
The technical and procedure success rates were similar between groups (Table 2 ). Of the 9 (8.6%) failures, 8 patients had residual stenosis >30% (6 in the Ranger DCB group and 2 controls) and 1 control patient had a TLR within 24 hours of the initial procedure (Table 2) . Nineteen patients had provisional stents placed at the operating investigator's discretion. Sixteen of these 19 had dissections (3 of 4 in the control group and 13 of 15 in the Ranger DCB group) and 3 had no dissections reported. The dissections in the control group were noted as types C (1) and D (2), and those in the Ranger DCB group were types B (2), C (6), D (3), and F (1); one did not have the type reported. No device deficiencies or unanticipated serious adverse device effects were reported.
Outcome Evaluation
Angiographic measurements were evaluable for 19 subjects in the control group and 47 subjects in the Ranger DCB group at 6 months. The mean core laboratory-assessed minimum lumen diameter at 6 months was 2.5±1.2 mm in the control group and 3.5±1.1 mm in the Ranger DCB group, yielding a late lumen loss of 0.76±1.4 mm in the control group and −0.16±0.99 mm in the Ranger DCB group (p=0.002; Figure 2) . Thus, the primary endpoint was met. The range of lumen loss values was −1.8 to 3.7 mm in the Continuous data are presented as the means ± standard deviation; categorical data are given as the counts/sample (percentage). b The ability to cross and dilate the lesion to achieve residual angiographic stenosis ≤30% (site assessment). Technical success with no major adverse events (defined as device/ procedure-related death, target limb major amputation, or target lesion revascularization) within 24 hours of the study procedure. d One target lesion revascularization in the control group occurred within 24 hours. Bailout stenting was not considered a target lesion revascularization.
control group and −2.0 to 3.2 mm in the Ranger DCB group (Figure 3) . Lumen loss remained significantly less for the Ranger DCB group (n=37; -0.18±1.1 mm) than for the control group (n=16; 0.63±1.5 mm; p=0.014) when patients with provisional stents were excluded from the analysis, and lumen loss did not significantly differ (p=0.839) between patients in the Ranger DCB group who did (n=10; -0.11±0.65 mm) and did not (n=37; -0.18±1.07 mm) have a bailout stent. Six-month patency rates, including freedom from binary restenosis as assessed by duplex ultrasound (91.7% vs 64.0%; p=0.005) and primary patency (87% vs 60%; p=0.014), were significantly greater for the Ranger DCB group than for subjects treated with a control balloon. The TLR rate for the Ranger DCB group was approximately half that of the control group at 6 months, although the difference was not statistically significant (5.6% vs 12%; p=0.475). No major limb amputations occurred through 6 months, and 1 death in the control group was reported, unrelated to the study procedure.
Symptom classifications were similar between the study groups at baseline (Figure 4) . At 6 months, a significant (p<0.001) improvement in distribution across Rutherford categories was observed in both groups. For the Ranger DCB group, a majority of subjects presented with no or mild symptoms at 6-month follow-up; specifically, 59.4% had symptoms classified as Rutherford category 0 and 21.9% were classified as category 1. The distributions between groups did not differ significantly at any time point. Clinical success was achieved by 76.0% (19/25) of subjects in the control group and 82.3% (51/62) of subjects in the Ranger DCB group (p=0.713) at 6 months.
As with the symptom results, ABI measurements were improved significantly over baseline in both groups at 6 months (p<0.02; Figure 5 ). Mean ABI was significantly greater in the Ranger DCB group at 6 months (0.95±0.17 vs 0.82±0.2; p=0.006), and the mean rate of hemodynamic success was higher (75.9% vs 54.2%), but the difference was not statistically significant (p=0.093). No significant differences were found between the Ranger and control groups for walking function (WIQ) or health-related quality of life (EQ-5D-3L, SF12v2) scores at baseline or 6 months (Supplemental Tables S2, S3, 
Discussion
Results of the randomized, controlled RANGER SFA study show a significant effect of the Ranger DCB on late lumen loss at 6 months, as well as a significant improvement in primary patency and patient symptoms. The safety profile for patients treated with the drug-coated balloon was similar to that for patients in the control group.
A significant effect of paclitaxel-coated balloons on 6-month late lumen loss when compared with uncoated balloons has been demonstrated previously, with differences between control and drug-coated balloon groups ranging from 0.50 to 0.66 mm in previous studies, 7, 8, 13, 19 while the between-group difference was 0.92 mm in the current trial. Likewise, reported average 6-month late lumen loss values for balloons with paclitaxel coatings range from −0.01 to 0.54 mm in previous studies, [7] [8] [9] 13, 19, 20 while it was −0.16 mm for the Ranger DCB group, indicating a slight lumen gain. Although comparisons with other studies are limited by differences in patient populations and study conduct, the 6-month benchmark suggests that the Ranger DCB produces an antirestenotic effect in the femoropopliteal arteries at least as well as other paclitaxel-coated balloons.
In general, a lumen loss value near zero may be interpreted as effective inhibition of restenosis. However, negative lumen loss could theoretically be achieved with lumen gain due to stenting or positive remodeling. 21 As in the RANGER SFA study, the randomized PACIFIER trial also reported a negative mean lumen loss (-0.01 mm) 6 months following DCB treatment and also had a bailout stent rate >20%. 7 The post hoc analyses conducted in the RANGER SFA study suggest that stenting does not account for the observed lumen gain in the Ranger DCB group at 6 months: the lumen loss value remained negative and significantly less than control when patients with stents were excluded, and lumen loss did not significantly differ between those who did and did not have a stent within the Ranger DCB group, suggesting a positive remodeling phenomenon. An enlarged lumen could also be caused by an aneurysm, evidenced by a lumen gain value double the size of the reference vessel diameter. Lumen gain of this magnitude was not observed. The minimum negative lumen loss value (or lumen gain) for the Ranger DCB group was 2.0 mm, which is less than half the mean reference vessel diameter, suggesting that aneurysm formation was not a factor. In addition, potential biases in lumen size measurement were minimized due to core laboratory blinding to group assignment. Taken together, these early results suggest that the late lumen loss observed in the Ranger DCB group is attributable to effective drug transmission to and deposition in the vessel wall, resulting in a significant reduction of restenosis compared with uncoated balloon angioplasty after 6 months. Follow-up at 12 months will confirm whether the 6-month lumen loss translates into favorable longer-term patency rates and clinical outcomes.
The design of the RANGER SFA study is similar to that of other randomized controlled trials of DCB treatment for femoropopliteal disease. The study sample included symptomatic patients with mainly TransAtlantic Inter-Society Consensus (TASC) A or B lesions, representing limited PAD, but approximately one-third of patients in both groups had occlusions. Patient characteristics at baseline were balanced between the study groups, with similar proportions of women in each group as well as similar prevalence of comorbidities, such as diabetes, current smoking, coronary artery disease, and renal impairment, all of which could affect treatment outcomes.
Limitations
An important limitation of the study endpoint analysis was that the number of patients with available 6-month angiographic images was less than was initially planned. Despite the underpowered analysis, a significant difference in late lumen loss was observed between Ranger and control groups. Another possible limitation for interpreting the effect of the DCB is the provisional stenting rate. Stenting was reserved for bailout situations and was performed in a minority of patients in both groups, with the resulting rates within the range reported in other studies. [7] [8] [9] 13, 19, 20 Although not statistically different, the rate was greater in the Ranger DCB group. Stenting did not appear to have a significant biasing effect on the late lumen loss evaluation in this study, as the post hoc analysis excluding patients with stents yielded results similar to the primary analysis, and DCBtreated patients with and without stents did not have significantly different mean lumen loss values. Primary stenting with bare metal and drug-eluting stents has shown superiority over balloon angioplasty alone, especially in longer lesions, 5, 22 but direct comparisons between DCBs and either bare metal or drug-eluting stents are not yet available.
Conclusion
Results of the RANGER SFA study suggest that treatment with the Ranger DCB effectively inhibits restenosis in symptomatic femoropopliteal disease and provides improved primary patency compared with standard treatment for TASC
